Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C BURNETT

Showing results (761-770 of 921) with videos related to

Pageof 93
Sort By:
Hypertension (Dallas, Tex. : 1979)|June 12, 2015
B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human HypertensionSara J Holditch, Claire A Schreiber, Ryan Nini, et al.
Developmental Medicine and Child Neurology|July 22, 2015
Brain structural and microstructural alterations associated with cerebral palsy and motor impairments in adolescents born extremely preterm and/or extremely low birthweightClaire E Kelly, Linda Chan, Alice C Burnett, et al.
Journal of the American Society of Nephrology : JASN|November 1, 1994
Resolution of posttransplant hypertension after liver transplantation despite impaired glomerular filtrationS C Textor, L Schwartz, V J Canzanello, et al.
Leukemia & Lymphoma|January 11, 2012
CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignanciesDaisuke Ito, Aric M Frantz, Christina Williams, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 2013
Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up studyValentina Cannone, Brenda K Huntley, Timothy M Olson, et al.
European Journal of Heart Failure|January 26, 2016
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failurePaul M McKie, John A Schirger, Sherry L Benike, et al.
Journal of the American College of Cardiology|March 15, 2000
Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibitionJ A Schirger, J A Grantham, I J Kullo, et al.
Radiography (London, England : 1995)|May 4, 2023
Integrating the patients' voice in designing and delivering a research study: The Yorkshire Cancer Research funded PREHABS study's experienceC Burnett, J C Bestall, S Burke, et al.
Cardiovascular Research|July 16, 2021
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacologyAlexandra Petraina, Cristian Nogales, Thomas Krahn, et al.
Journal of Cardiac Failure|May 14, 2008
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunctionTheophilus E Owan, Horng H Chen, Robert P Frantz, et al.
Pageof 93

Showing results (761-770 of 921) with videos related to

Sort By:
Pageof 93
Hypertension (Dallas, Tex. : 1979)|June 12, 2015
B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human HypertensionSara J Holditch, Claire A Schreiber, Ryan Nini, et al.
Developmental Medicine and Child Neurology|July 22, 2015
Brain structural and microstructural alterations associated with cerebral palsy and motor impairments in adolescents born extremely preterm and/or extremely low birthweightClaire E Kelly, Linda Chan, Alice C Burnett, et al.
Journal of the American Society of Nephrology : JASN|November 1, 1994
Resolution of posttransplant hypertension after liver transplantation despite impaired glomerular filtrationS C Textor, L Schwartz, V J Canzanello, et al.
Leukemia & Lymphoma|January 11, 2012
CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignanciesDaisuke Ito, Aric M Frantz, Christina Williams, et al.
Hypertension (Dallas, Tex. : 1979)|September 18, 2013
Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up studyValentina Cannone, Brenda K Huntley, Timothy M Olson, et al.
European Journal of Heart Failure|January 26, 2016
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failurePaul M McKie, John A Schirger, Sherry L Benike, et al.
Journal of the American College of Cardiology|March 15, 2000
Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibitionJ A Schirger, J A Grantham, I J Kullo, et al.
Radiography (London, England : 1995)|May 4, 2023
Integrating the patients' voice in designing and delivering a research study: The Yorkshire Cancer Research funded PREHABS study's experienceC Burnett, J C Bestall, S Burke, et al.
Cardiovascular Research|July 16, 2021
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacologyAlexandra Petraina, Cristian Nogales, Thomas Krahn, et al.
Journal of Cardiac Failure|May 14, 2008
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunctionTheophilus E Owan, Horng H Chen, Robert P Frantz, et al.
Pageof 93